IVTD’s patented human skin stem cell-derived hepatic cell model (hSKP-HPC or HepaSTARs) provides a sensitive and accurate assay for toxicity screening of novel drug candidates and the detection of drug-induced steatosis, phospholipidosis and acute liver failure, and has been tested using compounds with known toxicity, including sodium valproate and paracetamol. The hSKP-HPC model compares favourably with human hepatocytes, HepG2 and HepaRG™ cells in assessing hepatotoxicty.
led by Tamara Vanhaecke
miniaturisation of DILI prediction in hSKP-HPC model towards high-throughput drug screening
Mechanistic study of cholestatic liver injury using adverse outcome pathways as the basis for improved in vitro detection of liver toxicity.
led by Mathieu Vinken
Development of a primary hepatocyte spheroid culture system for the detection of chemical-induced cholestatic liver injury